Stéphane Marie. Oudard
Impact in
- Pulmonary and Respiratory Medicine top 0.01%
- Renal cell carcinoma treatment
- Prostate Cancer Treatment and Research
- Prostate Cancer Diagnosis and Treatment
- Cancer Research top 0.05%
- Cancer Genomics and Diagnostics
Papers in
-
- Renal cell carcinoma treatment 166
- Prostate Cancer Treatment and Research 139
- Prostate Cancer Diagnosis and Treatment 22
- Oncology 131
- Cancer Immunotherapy and Biomarkers 63
- Co-authors
- Thomas E. Hutson (11 shared papers)Sylvie Négrier (19 shared papers)Ronald M. Bukowski (9 shared papers)Robert John Motzer (13 shared papers)Cezary A. Szczylik (11 shared papers)Bernard J. Escudier (45 shared papers)Robert A. Figlin (7 shared papers)Piotr Tomczak (5 shared papers)
- Journals
- Annals of Oncology (69 papers)European Journal of Cancer (37 papers)European Urology (26 papers)Clinical Genitourinary Cancer (22 papers)Journal of Clinical Oncology (20 papers)
- Partner nations
- FranceUnited StatesUnited Kingdom
In The Last Decade
Stéphane Marie. Oudard
485 papers receiving 50.1k citations
Stéphane Marie. Oudard's Hit Papers
Peers
Comparison fields: 5 of 150
- Pulmonary and Respiratory Medicine 29.6k
- Cancer Research 10.1k
- Oncology 13.6k
- Molecular Biology 14.2k
- Immunology 3.6k
Countries citing papers authored by Stéphane Marie. Oudard
This map shows the geographic impact of Stéphane Marie. Oudard's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stéphane Marie. Oudard with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stéphane Marie. Oudard more than expected).
Fields of papers citing papers by Stéphane Marie. Oudard
This network shows the impact of papers produced by Stéphane Marie. Oudard. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stéphane Marie. Oudard. The network helps show where Stéphane Marie. Oudard may publish in the future.
Co-authors
The 25 scholars most cited alongside Stéphane Marie. Oudard, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 507 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma Hit paper breakdown → | 2007 | 4810 |
| 2 | Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer Hit paper breakdown → | 2004 | 4744 |
| 3 | Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma Hit paper breakdown → | 2007 | 4078 |
| 4 | Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial Hit paper breakdown → | 2010 | 2659 |
| 5 | Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial Hit paper breakdown → | 2008 | 2538 |
| 6 | Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma Hit paper breakdown → | 2009 | 1843 |
| 7 | Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial Hit paper breakdown → | 2017 | 1141 |
| 8 | Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer Hit paper breakdown → | 2018 | 1025 |
| 9 | Phase 3 trial of everolimus for metastatic renal cell carcinoma Hit paper breakdown → | 2010 | 983 |
| 10 | Sorafenib for Treatment of Renal Cell Carcinoma: Final Efficacy and Safety Results of the Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial Hit paper breakdown → | 2009 | 934 |
| 11 | Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell Carcinoma Hit paper breakdown → | 2018 | 676 |
| 12 | Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial Hit paper breakdown → | 2019 | 643 |
| 13 | Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial Hit paper breakdown → | 2013 | 610 |
| 14 | Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial Hit paper breakdown → | 2013 | 571 |
| 15 | Tertiary lymphoid structures generate and propagate anti-tumor antibody-producing plasma cells in renal cell cancer Hit paper breakdown → | 2022 | 560 |
| 16 | Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma Hit paper breakdown → | 2021 | 547 |
| 17 | 2012 | 528 | |
| 18 | Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial Hit paper breakdown → | 2009 | 498 |
| 19 | ctDNA guiding adjuvant immunotherapy in urothelial carcinoma Hit paper breakdown → | 2021 | 495 |
| 20 | Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial Hit paper breakdown → | 2021 | 488 |
About Stéphane Marie. Oudard
Stéphane Marie. Oudard is a scholar working on Pulmonary and Respiratory Medicine, Oncology, Cancer Research, Radiology, Nuclear Medicine and Imaging and Surgery, having authored 507 papers that have together received 51.3k indexed citations. Recurring topics across this work include Renal cell carcinoma treatment (166 papers), Prostate Cancer Treatment and Research (139 papers), Cancer Immunotherapy and Biomarkers (63 papers), Renal and related cancers (47 papers), Cancer Genomics and Diagnostics (39 papers), Bladder and Urothelial Cancer Treatments (37 papers), Radiopharmaceutical Chemistry and Applications (28 papers) and Prostate Cancer Diagnosis and Treatment (22 papers). The work is most often cited by research in Pulmonary and Respiratory Medicine (29.6k citations), Cancer Research (10.1k citations), Oncology (13.6k citations), Molecular Biology (14.2k citations) and Immunology (3.6k citations). Stéphane Marie. Oudard has collaborated with scholars based in France, United States and United Kingdom. Frequent co-authors include Thomas E. Hutson, Sylvie Négrier, Ronald M. Bukowski, Robert John Motzer, Cezary A. Szczylik, Bernard J. Escudier, Robert A. Figlin, Piotr Tomczak, Marc Dror Michaelson and Christine Théodore. Their work appears in journals such as Annals of Oncology, European Journal of Cancer, European Urology, Clinical Genitourinary Cancer and Journal of Clinical Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.